27 articles with Immunovia
Mats Grahn, CEO will present the IMMray™ antibody biomarker platform development pipeline and commercialisation strategies.
McGill, Yale and Universities of Pennsylvania and Massachusetts Join PanFAM-1, the Largest Ever Prospective Multicenter Clinical Study for Early Detection of Pancreatic Cancer
New centers give study near complete coverage of North American FPC sites in drive to validate IMMrayTM PanCan-d, the first blood based test for early detection of pancreatic cancer
Immunovia's IMMray™ platform for blood-based biomarker signatures offers exciting new opportunities to develop accurate diagnostic tests that can detect diseases at an early stage.
Immunovia Sponsors Primary Care Educational Symposium at Fenway Park in Honor of World Pancreatic Cancer Day
On November 15, 2018 Immunovia will sponsor a unique educational symposium for primary care clinicians in honor of World Pancreatic Cancer Day.
According to the instruction that was adopted at the Immunovia AB (Publ) AGM May 3 2018, the nomination committee should consist of four members
Immunovia Announces Strategic Focus Centered on IMMray™ Blood-based Biomarker Signatures for Rheumatoid Arthritis Within Autoimmunity
Encouraged by the promising discovery study results previously reported, Immunovia´s prime focus in autoimmunity testing will be to develop IMMray™ blood-based biomarker signatures for the management of rheumatoid arthritis.
Immunovia PanFAM-1 Clinical Trial now Available on ClinicalTrials.gov, the Largest Clinical Trials Database in the World
Immunovia has developed a blood based biomarker signature for early detection of pancreatic cancer called IMMray™ PanCan-d.
September 21 Research Roundup: Zombie Cells, Pancreatic Cancer, Household Cleaners and Obesity, a...
9/21/2018There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
On 3 April, trading in Immunovia's shares started on NASDAQ Stockholm's main market, where we are listed in the Mid Cap segment.
Invitation to presentation of Immunovia's Interim Report January-June 2018 and Comments to the Previously Published Autoimmunity Study Results
Immunovia will publish the company's interim report for the period January-June 2018 on Friday, August 24, at 08:30 a.m. CET.
Breakthrough in Autoimmune Testing - IMMrayTM Based Novel Biomarker Signature Identifies Patients With Anti-CCP Negative Rheumatoid Arthritis
Immunovia today announced that a new study confirms that the IMMray™ blood test successfully addresses one of the major challenges in autoimmune testing.
Journal of Clinical Oncology Publishes That IMMray™ PanCan-d Serum Biomarker Test Detects Early Pancreatic Cancer With 96% Accuracy
Immunovia AB announced that the prestigious Journal of Clinical Oncology (JCO) publishes the results of the major retrospective clinical validation study performed by Scandinavian and US researchers, showing that the IMMray™ PanCan-d serum biomarker microarray detects early pancreatic cancer with 96% accuracy.
Karolinska Institutet Participates in Immunovia's PanFAM-1 Prospective Clinical Study for Early Detection of Pancreatic Cancer Using Blood-based Test
Prospects rise for world's first national screening program.
The Board of Directors of Immunovia AB has adopted financial targets due to the fact the Company, as previously announced, will begin sales during second half of 2018.
Immunovia Accelerates Pancreatic Cancer Study of New Onset Diabetics by Adding Denmark's DD2 Diabetes Center for Strategic Research
Immunovia has today signed a letter of intent for collaboration with the Danish Center for Strategic Research into Type 2 Diabetes (DD2).
Immunovia Release: Sahlgrenska University Hospital First Swedish Site in the Largest Ever Prospective Clinical Study for Early Detection of Pancreatic Cancer
Immunovia today announced that Sahlgrenska University Hospital is the first Swedish site to be part of PanFAM-1, a multicenter prospective validation study for the early diagnosis in familiar pancreatic cancer high risk individuals.
Immunovia Initiates the World's Largest Study of New-Onset Diabetic Patients in a Prospective Pancreas Cancer Study Supported by Swelife
Immunova AB today announced the initiation of PanDIA-1, the world's largest prospective study of the new onset diabetes risk group for pancreatic cancer through a consortium with Lund and Uppsala Universities, Lund University Diabetes Center and Healthcare Region Skåne and Region Uppsala.
Immunovia announced today it has received a follow-on grant of SEK4.9 million from the Swelife Accelerator Innovation Program to support the last development studies of IMMray™ PanCan-d.
Immunovia Release: Final Data From Major Swedish Study Confirms That Immray Biomarker Microarray Differentiates Systemic Lupus Erythematosus (SLE) From Other Autoimmune Diseases With 96% Accuracy